Table 2. Summary of TKIs with anti-angiogenesis properties and their targets.

Medication	Molecular targets	Notable clinical response
Sorafenib (29)	VEGFR-2, VEGFR-3, PDGFR, KIT, FLT3, RAF	Improved PFS and TTP
Pazopanib (30)	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, KIT	No difference when added to standard cisplatin/pemetrexed
Sunitinib (31)	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, KIT, FLT3, RET	Improved PFS/ORR, no change in OS
Cediranib (32)	VEGFR-1, VEGFR-2, VEGFR-3	No change in PFS or OS
Motesanib (33)	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, KIT	Improved PFS, no change in OS
Linifanib (34)	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR	Improved PFS and OS
Vandetanib (35)	VEGFR-2, VEGFR-3, EGFR, RET	Improved PFS
Nintedanib (36)	VEGFR-1, VEGFR-2, VEGFR-3, PDGFR, FGFR	Improved PFS

TKIs, tyrosine kinase inhibitors; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet derived growth factor receptors; PFS, progression free survival; TTP, time to progression; ORR, overall response rate; OS, overall survival; FGFR, fibroblast growth factor receptor.